Alveus Therapeutics ApS: Financial statements 2025
CVR: 44689790
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Alveus Therapeutics ApS (CVR 44689790) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194. The solvency ratio was 91.6%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 22,056,673
- Profit/Loss
- DKK 2,096,582
- Equity
- DKK 59,681,194
- Total Assets
- DKK 65,129,049
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 22.1M | 2.1M | 59.7M | 2 |
| 2024 | - | -969K | -5.6M | -5.6M | 3 |
Official annual report
How creditworthy is Alveus Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 22, 2025, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.
As of November 15, 2025, Erik Voorspoels has stepped down as director of Alveus Therapeutics ApS.
As of September 22, 2025, Erik Voorspoels is registered as director of Alveus Therapeutics ApS.
As of September 22, 2025, Marie Louise Lindegaard has stepped down as director of Alveus Therapeutics ApS.
Alveus Therapeutics ApS has published its interim report for the period March 5, 2024 to December 31, 2024.
As of April 30, 2025, Rajkumar Kannan is registered as adm. dir. of Alveus Therapeutics ApS.
As of April 30, 2025, Nayan Gregory Parekh has stepped down as adm. dir. of Alveus Therapeutics ApS.
About Alveus Therapeutics ApS
Alveus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Rajkumar Kannan. The company's owners include Novo Holdings A/S, Alveus Therapeutics Inc. and FPCI BioDiscovery 7. The company has 12 employees (2026). In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194.
